SDT applies sonosensitizers that are activated by low-intensity ultrasound (US) radiation to transfer energy to the surrounding oxygen (O2), generating ROS to directly kill or induce apoptosis of tumor cells, meanwhile exposing calreticulin (CRT) to induce immunogenic cell death (ICD), with minimal damage to healthy tissues. The gene discussed is CALR; the disease is neoplasm.